CA3030230C - Formes solides d'inhibiteur de ttk - Google Patents

Formes solides d'inhibiteur de ttk

Info

Publication number
CA3030230C
CA3030230C CA3030230A CA3030230A CA3030230C CA 3030230 C CA3030230 C CA 3030230C CA 3030230 A CA3030230 A CA 3030230A CA 3030230 A CA3030230 A CA 3030230A CA 3030230 C CA3030230 C CA 3030230C
Authority
CA
Canada
Prior art keywords
crystal
cancer
compound
phosphoric acid
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3030230A
Other languages
English (en)
Other versions
CA3030230A1 (fr
Inventor
Heinz W. Pauls
Peter Brent Sampson
Sze-Wan Li
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Priority claimed from PCT/CA2017/050848 external-priority patent/WO2018014116A1/fr
Publication of CA3030230A1 publication Critical patent/CA3030230A1/fr
Application granted granted Critical
Publication of CA3030230C publication Critical patent/CA3030230C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des nouveaux co-cristaux d'un composé de formule (I) dans laquelle la molécule de co-formation étant le bisphosphate hémihydrate, des procédés pour la préparation de ces co-cristaux, des compositions pharmaceutiques contenant les co-cristaux, l'utilisation desdits co-cristaux dans la fabrication d'un médicament à utiliser dans le traitement du cancer et des méthodes de traitement de ces maladies chez l'homme ou l'animal par administration d'une dose thérapeutiquement efficace desdits co-cristaux.
CA3030230A 2016-07-18 2017-07-13 Formes solides d'inhibiteur de ttk Active CA3030230C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
US62/363,424 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (fr) 2016-07-18 2017-07-13 Formes solides d'inhibiteur de ttk

Publications (2)

Publication Number Publication Date
CA3030230A1 CA3030230A1 (fr) 2018-01-25
CA3030230C true CA3030230C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
AU2014336929B2 (en) Salt and crystal forms of PLK-4 inhibitor
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
AU2021221447B2 (en) Solid forms of TTK inhibitor
CA3030230C (fr) Formes solides d'inhibiteur de ttk
HK40007702B (en) Solid forms of ttk inhibitor
HK40007702A (en) Solid forms of ttk inhibitor
SG11202111003UA (en) Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
NZ790209A (en) Solid forms of ttk inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor